Outlook Therapeutics, Inc.
OTLK
$0.70
-$0.02-2.40%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 80.69% | -73.46% | 34.04% | 56.53% | -366.76% |
| Total Depreciation and Amortization | 1.00% | 1.35% | 1.02% | 1.03% | 1.04% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -184.32% | 540.09% | -139.35% | -83.08% | 201.15% |
| Change in Net Operating Assets | 328.66% | -172.56% | 49.25% | 136.90% | -185.97% |
| Cash from Operations | 47.60% | -20.70% | -4.00% | 28.24% | -51.21% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -100.00% | -- |
| Total Debt Repaid | -- | -- | -156.41% | 97.24% | -- |
| Issuance of Common Stock | -55.59% | 11.87% | -1.89% | -22.44% | 947.26% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -55.59% | 34.38% | -12.73% | -28.16% | 958.17% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -256.35% | 172.68% | -160.82% | -27.47% | 120.09% |